The Cost-Effectiveness of Celiac Disease Screening: An Analysis

By Staff Writer

March 10, 2024

Introduction

Celiac Disease (CD) is a prevalent autoimmune disorder, instigated by gluten, affecting approximately 1% of the UK’s population. This disease presents with a range of symptoms, including diarrhoea, bloating, and unexplained weight loss. However, many sufferers remain undiagnosed due to the non-specific nature of these symptoms. The only available treatment for CD is a strict, lifelong gluten-free diet. This can significantly impact the patient’s quality of life. Therefore, the accuracy and cost-effectiveness of a CD diagnosis is crucial.

The Consequences of Undiagnosed CD

Failure to promptly diagnose and treat CD can lead to severe complications. Damage to the small intestine’s surface and difficulties absorbing nutrients can result in malnutrition and anaemia. If left untreated, CD may also increase the risk of serious complications such as lymphoma and osteoporosis.

The Diagnostic Pathway for Celiac Disease Screening

The diagnostic pathway for CD involves identifying those at risk, serological testing to identify potential CD, and a biopsy of the small intestine to confirm the diagnosis. There are several serological tests available for CD in the UK. These include testing for immunoglobulin A (IgA) and IgA anti-tissue transglutaminase (tTG). Some guidelines also recommend IgA endomysial antibody (EMA) testing after tTG testing.

The Role of Genetic Testing in CD Diagnosis

Genetic testing, due to CD’s strong genetic basis, has the potential to be used as a “rule out” test. Absence of either of the human leukocyte antigen (HLA) DQ2/DQ8 genetic markers suggests it is highly unlikely that the person tested has CD. However, UK guidelines do not currently recommend HLA DQ2/DQ8 testing as an initial screening test for CD diagnosis.

The Cost-Effectiveness of Celiac Disease Screening

A recent study from the UK aimed to estimate the most cost-effective pre-test probability which all patients should be screened for in the country. They also aimed to address which serological tests should be used. Furthermore, whether genetic testing should be included, and whether a confirmatory biopsy would be needed. Lastly, they aimed to identify uncertainties that have the greatest impact on cost-effectiveness results, thus identifying priorities for future research.

Comparative Analysis with Other Studies

Their findings, which advocate for the cost-effectiveness of IgA EMA, IgA tTG, and HLA testing, either alone or in combination, for at-risk patients align with previous models. For instance, a study by Ladabaum 2004 found tTG to be cost-effective at $50,000 if the pre-test probability was 2% and at $100,000 if the pre-test probability was 1.1%. Similarly, Herchcovici 2010 used a Markov model to conclude that mass screening via serological test followed by biopsy was cost-effective compared to no screening.

International Perspectives on CD Screening

In an international context, Mohseninejad 2013 found that screening patients with irritable bowel syndrome (IBS) symptoms for CD was cost-effective in the Dutch setting. Meanwhile, Norström et al, 2021 discovered population screening at age 12 using IgA EMA to be cost-effective at a Є50,000 per quality-adjusted life-year (QALY) willingness-to-pay (WTP) threshold, compared with no screening in the Swedish setting. The model by Keeney et al, largely followed the evidence-based structure used in the National Institute of Clinical Excellence (NICE) guideline model, with deviations based on clinical opinion and analysis of the Clinical Practice Research Datalink (CPRD) data sets.

Conclusion

In conclusion, the economic burden of CD and its impact on the quality of life of patients necessitates a cost-effective diagnostic strategy. Current evidence suggests that serological tests, such as IgA EMA and IgA tTG, in combination with HLA testing, provide a cost-effective approach for the screening of at-risk patients. It’s worth noting that the pre-test probability of CD significantly impacts these tests’ cost-effectiveness. We need more research to clear uncertainties in the diagnostic pathway. It’s also essential to enhance screening strategies for CD.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.